Table 2.
Prevalences of hrHPVs, grouped by SIL status
| Genotype | Cervicitis/NILM | ASC-US | LSIL | HSIL |
|---|---|---|---|---|
| (N = 1234) | (N = 58) | (N = 112) | (N = 75) | |
| 16 | 222 (18.0) | 10 (17.2) | 27 (24.1) | 41 (54.7)*** |
| 18 | 153 (12.4) | 7 (12.1) | 16 (14.3) | 4 (5.3)** |
| 31 | 101 (8.2) | 4 (6.9) | 9 (8.0) | 5 (6.7) |
| 33 | 79 (6.4) | 7 (12.1) | 12 (10.7) | 8 (10.7) |
| 35 | 58 (4.7) | 2 (3.4) | 4 (3.6) | 1 (1.3) |
| 39 | 73 (5.9) | 0 (0.0) | 4 (3.6) | 0 (0.0) |
| 45 | 41 (3.3) | 1 (1.7) | 4 (3.6) | 0 (0.0) |
| 51 | 74 (6.0) | 2 (3.4) | 13 (11.6) | 2 (2.7) |
| 52 | 295 (23.9) | 16 (27.6) | 35 (31.3) | 12 (16.0)* |
| 56 | 49 (4.0) | 2 (3.4) | 4 (3.6) | 3 (4.0) |
| 58 | 194 (15.7) | 12 (20.7) | 20 (17.9) | 22 (29.3)** |
| 59 | 29 (2.4) | 2 (3.4) | 2 (1.8) | 0 (0.0) |
| 66 | 53 (4.3) | 6 (10.3) | 4 (3.6) | 3 (4.0) |
| 68 | 105 (8.5) | 4 (6.9) | 8 (7.1) | 0 (0.0)** |
SIL, squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
***P < 0.05 vs. cervicitis/NILM, ASC-US and LSIL groups; **P < 0.05 vs. cervicitis/NILM and LSIL groups; *P < 0.05 vs. cervicitis/NILM group. Percentages >10 are shown in bold.